POLBF News and Press, Poolbeg Pharma plc Ord GBP 0.0002 From 04/30/24

Significant pipeline advancements Strategic expansion into cancer immunotherapy-induced CRS unlocking a market opportunity exceeding US$10Bn Key senior management hires LONDON, UK / ACCESSWIRE / April 30, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF); 'Poolbeg' or the 'Company')...

LONDON, UK / ACCESSWIRE / April 29, 2024 / TR-1: Standard form for notification of major holdings This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingd...

Notice of Allowance for Significant POLB 001 Patent in United States Notice of Allowance for Immunomodulator II further strengthens robust intellectual property portfolio LONDON, UK / ACCESSWIRE / March 20, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) ('Poolbeg' or the 'Company'), a biop...

(NewsDirect) Poolbeg Pharma chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss his new hands-on role at the company. Stepping up as the executive chairman at Poolbeg Pharma, Friel expressed his intention to replicate the success he achieved with hVIVO, another company...

LONDON, UK / ACCESSWIRE / February 19, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has recei...

2024-02-15 04:01:48 ET More on Poolbeg Pharma Historical earnings data for Poolbeg Pharma Financial information for Poolbeg Pharma Read the full article on Seeking Alpha For further details see: Poolbeg Pharma announces board role change and launch of EIP

LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Bo...

(NewsDirect) Poolbeg Pharma Plc chief business officer David Allmond joined Proactive's Stephen Gunnion with details of independent research that confirms the massive market potential for Poolbeg's POLP 001 in cancer immunotherapies. This asset is being explored for its ability to pot...

Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Former Amryt team's arrival supports increasing focus upon Rare and Orphan Diseases LONDON, UK / ACCESSWIRE / February 1...

(NewsDirect) Poolbeg Pharma PLC's newly appointed Vice President of Clinical Operations Laura Maher joined Proactive's Stephen Gunnion to discuss her role at the company. Maher detailed her responsibilities at Poolbeg, emphasising her leadership in developing and managing clinical pro...